Lee Schalop News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lee schalop. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lee Schalop Today - Breaking & Trending Today

TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders

Regulatory News:

TME Pharma N.V. , a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment , announced today that the annual. ....

France General , United States , Noord Holland , Merck Keytruda , Pharmanv Euronext , Lee Schalop , Board Observer At Chimerix Inc , Merck Sharp Dohme Corp , Albert Einstein College Of Medicine , University Wharton School , Articles Of Association , University Of Pennsylvania , Freshfields Bruckhaus Deringer , Vagelos Program In Life Sciences , Credit Suisse , College Of Arts , Morgan Stanley , Regulatory News , Euronext Growth Paris , Corporate Governance , New York , Chief Executive Officer , Oncoceutic Chief Operating Officer , Chief Business Officer , Albert Einstein College , Wall Street ,

TME Pharma N.V.: TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment ....

United States , France General , Noord Holland , Merck Keytruda , Arthur Rouill , Guillaume Van Renterghem , Lee Schalop , Pharmanv Euronext , Aram Mangasarian , Merck Sharp Dohme Corp , College Of Arts , University Wharton School , Vagelos Program In Life Sciences , Albert Einstein College Of Medicine , Morgan Stanley , Articles Of Association , University Of Pennsylvania , Freshfields Bruckhaus Deringer , Credit Suisse , Board Observer At Chimerix Inc , Regulatory News , Euronext Growth Paris , Corporate Governance , New York , Chief Executive Officer , Oncoceutic Chief Operating Officer ,

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET
| Source:
Chimerix, Inc.
Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Compelling Response Rates to Date; Defined Regulatory Path to Registration
Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million
Management to Host Conference Call at 8:30 a.m. ET Today
DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical t ....

United States , Patrick Wen , Wafik El Deiry , Michelle Laspaluto , Morgan Lewis , Mike Sherman , Wolfgang Oster , David Schull , Lee Schalop , Oncoceutics Inc , Neurology At Harvard Medical School , Dragon Master Foundation , World Health Organization , Drug Administration , Chadtough Foundation , Society Of Neuro , Exchange Commission , National Brain Tumor Society , Musella Foundation , Dana Farber Cancer Institute , Clinical Development Plan , Response Rates , Defined Regulatory Path , Data Anticipated , Support Potential Registration , Estimated Market Opportunity ,